Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Sandler Discusses Hypofractionation in Prostate Cancer

March 8th 2018

Howard M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.

Expert Addresses Advances and Challenges in Bladder Cancer

March 7th 2018

Mark Tyson, MD, discusses the management of localized advanced bladder cancer, the promise of immunotherapy, and his advice for urologists treating patients with bladder cancer.

Dr. Kim Discusses Cytoreductive Nephrectomy in Metastatic RCC

March 7th 2018

Hyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.

FDA Approves 4-Week Nivolumab Dosing Schedule

March 6th 2018

The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.

Optimal Sequencing Key to Capitalizing on RCC Advances

March 6th 2018

Thai H. Ho, MD, PhD, discusses treatment advances in first-line RCC and how biomarker development and optimal sequencing are critical next steps to building on recent breakthroughs.

Dr. Balmanoukian on Immunotherapy Advancements in GU Cancers

March 5th 2018

Ani Balmanoukian, MD, director of Thoracic Oncology, associate director of the Phase I Immune-Oncology Program, The Angeles Clinic and Research Institute, discusses immunotherapy advancements in genitourinary cancers.

A Call to Arms in Urology

March 4th 2018

Prostate cancer continues to be the most common newly diagnosed solid tumor in men over 50 years and the second leading cause of cancerspecific mortality.

Dr. Tyson on Rationale For Neoadjuvant Chemotherapy in Bladder Cancer

March 3rd 2018

Mark D. Tyson, MD, urologic oncologist, Mayo Clinic, discusses 2 trials that have shaped physicians’ opinions on the use of neoadjuvant chemotherapy in patients with bladder cancer.

Dr. Singh on Patient Selection for Immunotherapy in Bladder Cancer

March 2nd 2018

Parminder Singh, MD, Hematologist/Oncologist, Mayo Clinic, discusses treatment selection for patients with bladder cancer. At this point, patient selection is based on the approval or labeling indications of the drug, where the patient lies in the spectrum of disease, and whether or not they have any alternative options.

Dr. Ho on How Molecular Subtypes Affect Sequencing

March 2nd 2018

Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses common molecular subtype and phenotype alterations in the epigenetic pathway that are used to predict response to treatment.

DDR Alterations Associated With Increased Anti-PD-1/PD-L1 Activity in Bladder Cancer

March 2nd 2018

Alterations in DNA damage response and repair genes were associated with an increased response to anti-PD-1/PD-L1 antibodies in patients with metastatic urothelial carcinoma.

Dr. Figlin on the Safety Profile of Immuno-Oncology Agents in Kidney Cancer

March 1st 2018

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the tolerability and toxicity of immune-oncology agents in kidney cancer.

Dr. Plimack on Immunotherapy Combinations in Bladder Cancer

February 27th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses immunotherapy combinations for patients with bladder cancer.

European Panel Recommends Against Adjuvant Sunitinib for High-Risk RCC

February 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against approving sunitinib for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are high risk for recurrence.

Flexible Scope Indication Approved for Bladder Imaging Agent

February 26th 2018

The FDA recently approved a supplemental new drug application for Blue Light Cystoscopy with Cysview for surveillance of bladder cancer. Cysview is currently indicated for use for detection of nonmuscle-invasive bladder cancer.

Urology Practice Succeeds With Transparency, Upfront Payment Model

February 25th 2018

Wichita Urology, the largest independent urology practice in Wichita, Kansas, have built their success over 60 years partly by holding frequent meetings, which they say build camaraderie and make it possible to address needs quickly.

Dr. McKay on Unmet Needs for RCC

February 23rd 2018

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses unmet needs for patients with renal cell carcinoma (RCC).

Dr. Sonpavde on Novel Prognostic Marker for Atezolizumab in Bladder Cancer

February 20th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a novel prognostic marker for patients with advanced bladder cancer being treated with the PD-L1 inhibitor atezolizumab (Tecentriq).

Immunotherapy Trials Offer Hope in Advanced Penile Cancer

February 20th 2018

Guru Sonpavde, MD, discusses the importance of clinical trial enrollment for patients with penile cancer.

Dr. Bellmunt on Challenges With Immunotherapy in Bladder Cancer

February 20th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses challenges with immunotherapy in bladder cancer.